Company Directory / Biotechnology

Public · LSE:ONT.LFor profitBiotechnologyOxford, United Kingdom
Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology.
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology, the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on… Read all
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology, the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats, from pocket to population scale, and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
Size
501-1000 people: larger than 95% of companies with a size listed. 1,334 people list it on LinkedIn.
Age
21 years old.
Reach
Website ranked #269,326 in the world for traffic, about 150k visits a month. 116,564 followers on LinkedIn.
BiopharmaBiotechnologyGeneticsHealth DiagnosticsNanotechnologyDNA sequencingNext Generation Sequencing
Funding, as listed
$1.1B raised in total
What the source datasets report. We have not watched these rounds ourselves.
Everything the source datasets list about Oxford Nanopore Technologies, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Growth, as the source summarises it
Oxford Nanopore Technologies reported widening losses, delaying its break-even point. The company has also entered into strategic collaborations, including a partnership with SeqOne for rare disease DNA diagnostics and another with Plasmidsaurus to advance plasmid sequencing. Additionally, Oxford Nanopore Technologies has made a strategic shift targeting growth.
Summaries written by the source dataset, not by us, and not checked.
Biotechnology in United Kingdom.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.